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Abstract
The literature on the use of molecularly imprinted polymers (MIPs) in antibody-like sorbent assay using radio, fluoro and enzyme-linked
approaches is comprehensively reviewed, and their current status discussed. Although immunoassays are still commonly carried out using
antibodies, recent developments have demonstrated that molecularly imprinted polymers can be viable alternatives. It is predicted that both
traditional antibody-based and MIP sorbent assays will continue to develop in parallel, with each having superiority in certain areas.
© 2004 Elsevier B.V. All rights reserved.
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1. Introduction
During the last decade, molecularly imprinted materials
have been used in a range of techniques (liquid chromatog-
raphy, solid phase extraction, capillary electrochromatogra-
phy, biosensors, catalysts, bio imprinting, binding assays)
and a number of approaches (covalent, non-covalent, sacrifi-
cial spacer, metal-coordination, stoichiometric non-covalent
interactions) have been applied. Here we review the current
state of the use of molecularly imprinted polymers (MIPs)
as replacements for antibodies in sorbent assays. Immunoas-
says, which rely on specific interactions between antibodies
and antigens, are in routine laboratory use for quantification
of many analytes in biological fluids [1]. With the advent
of production of monoclonal antibodies through hybridoma
cell technology [2] and significant technical progress in de-
tection systems, assays with high sensitivity and specificity
have been developed [3]. However, use of animals in the
production of antibodies is of concern in some areas so that
development of alternative methods is preferable.
Antibody-based assays still present several fundamental
limitations due to the nature of the recognition element in-
volved. Antibodies are relatively chemically and physically
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unstable, which shortens their storage lifetime, limits their
use to aqueous media, and makes them very sensitive to
pH and temperature [4]. Furthermore, in the case of small
molecules, the antigen itself is not immunogenic and addi-
tion of a carrier hapten moiety, such as bovine serum albu-
min (BSA), is needed to elicit an immune response [5]. It
is not possible to produce immunogenic derivatives of all
potential analytes. Depending on the choice of the hapten
derivative, the immunisation procedure will lead to antibod-
ies with different properties and affinities [6]. Although con-
siderable efforts have been made to find ways of preparing
antibodies with improved stability (antibody fragments, re-
combinant antibodies, etc.) [7,8], the current techniques may
still not be time and cost effective.
MIPs result from the polymerisation of monomeric units
in the presence of a template molecule (Fig. 1). Subsequent
removal of the template results in cavities whose shape,
size, functionality and spatial arrangement are complemen-
tary to the imprinted molecule [9–11]. These recognition
sites with predetermined selectivity, enable MIPs to bind
target molecules with similar affinities and specificities to
their natural counterparts [12]. Furthermore, MIPs are sta-
ble and extremely robust. Their ability to recognise their
template and related molecules can remain unaffected after
treatment with strong base, strong acid, all common organic
solvents and extremes of temperature [13,14]. This unique
physical and chemical stability allows their use under con-
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Fig. 1. Schematic representation of MIP synthesis and a competitive enzyme-linked molecularly imprinted sorbent assays: (I) functional monomers and
template interact via non-covalent interaction to form a complex, polymerisation is carried out after addition of the crosslinker and the initiator; (II) the
template is removed leaving imprinted cavities in the polymer matrix; (III) after further processing the imprinted polymer can be used in an assay where
the analyte (template) and an enzyme-labelled analyte compete for the available binding sites; (IV) upon separation of the free and bound fraction the
enzyme activity is evaluated in the supernatant.
ditions where antibodies are unemployable (Table 1) and, as
they are synthetic materials, they do not require the use of
animals at any stage of the production, which make them
more socially acceptable.
2. Radio-molecularly imprinted sorbent assays
In 1993, Mosbach’s group reported the first molecularly
imprinted sorbent assay (MIA) [12] in which polymers im-
printed with either theophylline or diazepam replaced an-
tibodies in competitive immunoassay-like experiments. Al-
though the analyte needed to be extracted from human serum
and transferred into a non-polar organic medium prior to
analysis, these radioligand-binding assays were equivalent,
Table 1
Comparison between MIPs and antibodies
MIPs Antibodies
Can be used in both aqueous and organic media Restricted to aqueous conditions
Synthetic: no use of animals Biological production involving animals
High chemical, physical and thermal stability Very fragile
Simple storage requirements Need to be lyophilised and may denature upon long period storage
Preparation: fast Preparation: time-consuming but monoclonal strategy allows large
long-term production once antibody is optimised
Require a relatively large amount of template Require a relatively small amount of antigen
Non-covalent approach: no need for derivatisation.
Covalent approach: functional monomer–template
complex needs to be synthesised
Necessary to derivatise small non-immunogenic molecules in
order to produce immune response
Controllable batch to batch reproducibility Polyclonal antibodies are specific to each animal.
Monoclonal antibodies allow batch reproducibility
Reusable Non-reusable
in terms of cross-reactivity, to assays performed with mono-
clonal antibodies. Subsequent work using anti-morphine and
anti-enkephalin polymers confirmed the potential of MIPs
as antibody mimics in immunoassays [15] and, in the case
of the morphine imprinted polymer, demonstrated that ef-
ficient binding could be achieved in an aqueous environ-
ment. Although affinity and selectivity were reduced com-
pared with values obtained in organic solvents, they were
still comparable with those obtained for other antibody sys-
tems (Table 2). These extremely encouraging results were
followed by a plethora of reports of other MIP sorbent assays
(Table 3). An (S)-propranolol MIP sorbent assay, demon-
strated greater stereoselectivity than an antibody assay [16]
(cross-reactivity towards (R)-propranolol 1% for MIP, com-
pared with 5–7% for natural counterpart). Further to this
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Table 2
Cross-reactivity of opiates to the anti-morphine MIP and anti-morphine antibodies (adapted from reference [15])
Ligand Relative cross-reactivity (%)
MIP Antibody fragment
In buffer In toluene a b c d
Morphine 100 100 100 100 100 100
Codeine 25 4.7 18 104 36 <0.1
Hydromorphone 15 6.0 112 9.8
Normorphine 9.9 8.3
Heroin 8.3 2.3
Naloxone 0.4 <0.1 <0.5 0.1 0.7 <0.1
Naltrexone 0.3 <0.1 0.1 0.2 0.1
Leu-enkephalin 0.1
Met-enkephalin 0.1 0.1
study, the first assay of biological samples without prior
clean up was carried out [17]. The assay was shown to be
effective, reproducible and accurate with 60% plasma in
the incubation mixture. However, although the analysis of
the urine samples could be performed at pH 6 which was
shown to be optimal for high specific binding [16], anal-
ysis of plasma samples under physiological condition (pH
7.4), resulted in a significant increase in non-specific bind-
ing and additional optimisation was needed. More recently,
theophylline imprinted microspheres have been used to de-
velop a competitive radioassay [18]. This approach resulted
in higher binding site densities and more rapid kinetics.
Small molecules, such as atrazine, need to be linked to a
protein in order to elicit an immune response [5] but such
derivatisation is not needed when using a molecular im-
printing technique. Anti-atrazine polymers have been syn-
Table 3
Examples of radio-molecularly imprinted sorbent assays
Template Polymer Affinity, KD (M) Binding capacity (mol/g) Ref.
(S)-theophylline MAA/EDMA/CHCl3 H: 0.35 ± 0.048, L: 65 ± 16 H: 0.016, L: 1.3 [9]
TFMA/DVB 0.01 0.023 [18]
MAA/TRIM/ACN H: 0.32, L: 49.5 H: 56.8 ± 11.8, L: 2120 [23]
Diazepam MAA/EDMA/CHCl3 H: 0.018, L: 60 ± 74 H: 0.0062, L: 1.2 ± 0.93 [9]
Morphine MAA/EDMA/ACN H: 0.092a/1.2b, L: 8.9a/24b H: 1.2a/0.78b, L: 39a/6.9b [15]
Leu–enkephaline MAA/EDMA/ACN H: 0.13a/0.1b, L: 43a/440b H: 0.017a/0.0038b, L: 1.01a/36b [15]
(S)-propranolol MAA/EDMA/toluene H: 0.04a/0.04b, L: 23a/4.1b H: 2.0a/0.63b, L: 38a/28b [16,17]
Proteins Trehalose/C3F6 nd nd [21,22]
Atrazine MAA/EDMA/CH2Cl2 800c 7.7c [19,24]
17-Oestradiol MAA/TRIM/ACN H: 2.1, L: 0.96 H: 2.98 ± 0.75, L: 0.007 ± 0.76 [18]
2,4-D 4-VP/EDMA/CH3OH/H2O nd nd [25]
Yohimbine MAA/EDMA/CHCl3/DMF H: 0.06a/0.12b, L: 4.8a/62b H: 0.12a/0.06b, L: 1.1a/11b [26]
MAA/EDMA/CH3OH H: 47a/2.3b, L: 5400a/150b H: 0.96a/0.11b, L: 59a/7.4b [26]
Corynanthine MAA/EDMA/CHCl3/DMF H: 37a/5.6b, L: 1300a/170b H: 70a/2.5b, L: 840a/28b [26]
MAA/EDMA/CH3OH H: 330a/25b, L: 2500a/640b H: 11a/3.9b, L: 64a/57b [26]
Corticosterone MAA/EDMA/THF H: 1.23 ± 0.43, L: 840 H: 0.37 ± 0.12, L: 130 ± 60 [27]
Cortisol MAA/EDMA/THF H: 0.57 ± 0.16, L: 1590 H: 0.21 ± 0.05, L: 280 ± 120 [27]
nd: not determined; MAA: methacrylic acid; TFMA: trifluoromethacrylic acid; EDMA: ethylene glycol dimethacrylate; TRIM: trimethylolpropane
trimethacrylate; 4-VP: 4-vinyl pyridine; DVB: divinylbenzene; ACN: acetonitrile; H: high affinity sites; L: low affinity sites.
a Aqueous environment.
b Organic solvent.
c Determined by frontal chromatography.
thesised [19] and, although the sensitivity of the MIP sor-
bent assay was less than a reference enzyme-linked im-
munosorbent assay (ELISA), it was able to differentiate the
related herbicide propazine, whereas the ELISA showed a
cross-reactivity of more than 200%. The solvent compati-
bility of molecularly imprinted assays is of particular sig-
nificance. Whereas antibody-based systems are limited to
aqueous environments, molecularly imprinted assays can
be performed in apolar solvents which is particularly use-
ful when the target analyte is hydrophobic. This advan-
tage has been exploited in an assay for cyclosporin, which
was developed in diisopropyl ether [20]. As cyclosporin is
an immunosuppressive drug, it is difficult to raise antibod-
ies against it. The analyte was recovered from haemolysed
whole blood samples by liquid–liquid extraction. The con-
centration of cyclosporin was estimated using both MIA and






DTAF: 5-([4,6-dichlorotriazin-2-yl]amino)fluorescein; 2,4-D: 2,4-dichlorophenoxyacetic acid;   CMMC:    7-carboxymethoxy-4-methyl- 
coumarin; CAP:  chloramphenicol; CAP-MR:  chloramphenicol methyl red. 
Atrazine (III) DTAF (II) 
2,4-D (V) CMMC (VI)















































Fig. 2. Structures of some templates and their fluorescent counterparts used in competitive fluorescence molecularly imprinted sorbent assays.
an enzyme-multiplied immunoassay (EMIT). Optimisation
of the MI assay showed that unknown matrix component ef-
fected its sensitivity and it was not possible to determined
concentration <100 ng/ml with accuracy. However, unlike
the EMIT, the MIA was able to measure the concentration of
cyclosporin and its first generation metabolites (AM1, AM9
and AM4N) with approximately equal response. It was ob-
served that this might have clinical value.
It is often considered that molecular imprinting is more
suitable for use with small stable molecules rather than
with more fragile and complex macromolecules. However,
surface imprinting of proteins, such as albumin, lactalbu-
min, immunoglobulin, lysozyme and ribonuclease, has been
achieved using carbohydrates and a plasma deposition tech-
nique [21]. Proteins were adsorbed onto a mica surface and
coated with the disaccharide trehalose. A film of hexaflu-
oropolymer created by plasma deposition was further at-
tached to a solid support and, after removal of the mica
and extraction of the template, an imprinted surface com-
plementary to the protein was obtained. Competition exper-
iments using 125I radiolabelled proteins demonstrated that
these surfaces had a higher affinity for their template than
other related molecules [22]. They also confirmed that spe-
cific recognition relied on a dynamic adsorption-exchange
process, which, for larger less rigid molecules, could be an
issue.
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3. Fluoro-molecularly imprinted sorbent assays
Radiolabelled compounds are structurally virtually iden-
tical to their unlabelled counterparts, are often commer-
cially available, and can give rise to sensitive assays. How-
ever, there are health and safety implications associated with
the use of radioactive materials and attention has been di-
rected to detection systems involving less hazardous materi-
als. Fluorescence detection is a possible alternative [28] and
pseudo-fluoroimmunoassays based on molecular imprinting
have been developed.
3.1. Competitive and displacement assays
Piletsky et al. was the first to describe a competitive
molecularly imprinted assay using a fluorescent reporter
[29]. Triazine (I) and 5-[(4,6-dichlorotriazin-2-yl)amino]-
fluorescein [DTAF (II)] (Fig. 2), a fluorescent triazine
derivative, competed for the available binding sites, fluo-
rescence of the supernatant was proportional to the triazine
concentration, and the polymer was selective for triazine
over atrazine (III) and simazine (IV). This group also
developed a competitive assay using DTAF based on an
atrazine imprinted membrane [30]. Following work using
radiolabelling [25], Haupt et al. developed a competitive
fluoroassay for 2,4-dichlorophenoxyacetic acid (2,4-D) (V)
in both organic and aqueous solvents [31,32]. The detection
limit was similar to that of a radioassay (0.1M) and the
equilibration time was half that used for the triazines. Fur-
thermore, as found with the MIP radioassay, cross-reactivity
of the polymer towards 2,4-dichlorophenoxyacetic acid
methyl ester (2,4-D-OMe) was lower than that reported for
immunoassays.
Table 4
Examples of homogeneous pseudo-fluoroimmunoassays
Template Polymer Fluorescent chromophore Fluorescence Ref.
Cholesterol EDMAa M1 0b [40]
(l)-Tryptophan EDMAc ((2-N-dansyl)ethyl) 3,3-dimethylacrylate −d, +++d,e [41]
Sialic acid M2/aA/EDMA/DMFa Primary amine/OPA +++d [42]
(d)-Fructose HEMA/EDMAa Anthracene/boronic acid conjugate +++d [43]
cAMP HEMA/TRIM/CH3OHc vb-DMSAP −−−d,f [44,47,48]
Carboxamidrazone derivative EDMA/CHCl3c 3-Acrylamido-5-(2-methoxy-1-naphthylidene)-rhodamine −−−b [45]
Carboxamidrazone derivative TRIM/toluenec −−−b [46]
9-Ethyladenine MAA/EDMA/CHCl3c Zn-porphyrin −−−b [49]
(−)-Cinchonidine MAA/EDMA/CHCl3c Zn-porphyrin −−−b [50]
Histamine MAA/EDMA/CHCl3c Zn-porphyrin −−−b [51]
Toluic acid In solution (preliminary study) 9-(Guanidinomethyl)-10-vinylanthracene +++b,g [52]
+: increase in the fluorescence; −: decrease in the fluorescence; 0: no change in the fluorescence; aA: allylamine; M1: acrylic
acid 4-(2-{4-[2-(4-hydroxy-3,5-dimethoxy-phenyl)-vinyl]-phenyl}-vinyl)-2,6-dimethoxy-phenyl ester; M2: sialic acid-o((4-vinylphenyl)boronate); OPA:





e p-Nitrobenzaldehyde used as quencher.
f cAMP K = 2.9M.
g Toluic acid K = 8.3M.
As a comparator to the flow through format used in
some immunoassays [33], displacement of a fluorescent
probe from an MIP-HPLC stationary phase was suc-
cessfully used to determine chloramphenicol [34,35] and
l-phenylalaninamide [36] in biological samples, although
no competition could be achieved between oestradiol and
different fluorescent derivatives [37].
Chow et al. adopted an approach in which they deriva-
tised dl-homocysteine with a pyrenyl moiety and imprinted
this entire fluorescent molecule rather than the analyte [38].
Then, using the catalytic property of the imprinted polymer
[39], they detected dl-homocysteine by in situ fluorescent
derivatisation. The response of the polymer was linear in the
concentration range found in plasma and the specificity of
the detection was enhanced by the fact that the imprinted
polymer acted as a “footprint catalyst” for the derivatisation
reaction [39].
3.2. Homogeneous assays
An advantage of fluorescence detection is the possibility
of developing homogeneous assays where it is not necessary
to separate the bound and unbound analyte fractions [28].
A range of fluorescent functional monomers were incorpo-
rated and rebinding of the template was shown to modify
the fluorescence of the matrix (Table 4). Where no signif-
icant fluorescence intensity change was observed [40,41],
the alternative solution of using a quencher as a competitive
agent was applied [41]. Piletsky et al. [42] and Wang et al.
[43] adopted a more successful covalent approach in which
the fluorescence was modified upon rebinding of the tem-
plate. However, the sialic acid imprinted polymers showed
a high cross-reactivity towards galactose [42]. Turkewitsch
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et al. [44] designed and synthesised a fluorescent monomer
able to interact with purine nucleotides (cAMP and cGMP)
via electrostatic interactions. In an aqueous environment
the anti-cAMP polymer was able to rebind the template
selectively with a single affinity constant (KD = 2.9M),
which was uncommonly high for non-covalently imprinted
polymers. Rathbone et al. [45] synthesised imprinted poly-
mers incorporating a fluorescent monomer able to interact
with the template via hydrogen bonds and used these in
high-throughput screening of a library of potentially anti-
tubercular drugs [46]. Matsui et al. developed a homoge-
neous system based on cooperative interactions between
methacrylic acid and porphyrin-based functional monomers
[47] where binding of the template (9-ethyladenine or
(−)-cinchonidine) altered the fluorescence of the porphyrin
ring [48,49].
High fluorescent backgrounds may impair the detection
limit and sensitivity of fluoroassays and Wandelt et al. [50]
adopted a different approach to circumvent this problem.
They used the fluorescent functional monomer of Turke-
witsch et al. [44] coupled with time-resolved fluorescence
spectroscopy to study binding of cAMP [51] and found that
the fluorescent lifetime decreased with increasing template
concentration, resulting from the formation of tightly bound
stable complexes within the cavities.
4. Enzyme-linked molecularly imprinted sorbent assays
Few enzyme-linked molecularly imprinted sorbent assays
have been reported to date (Table 5). Surugiu et al. [53] first
demonstrated that it was possible to use an enzyme-labelled
conjugate as a competitive probe. Tobacco peroxidase
(TOP) was used as the label and an assay developed for
2,4-dichlorophenoxyacetic acid (2,4-D) based on either
colourimetric or chemiluminescent detection. By measuring
the activity of the enzyme in the supernatant it was shown
that 2,4-D was able to compete with 2,4-D-TOP for the
available binding sites. Quantification of the analyte was
possible at concentrations ranging from 40 to 60 g/ml and
1 to 200g/ml using either colourimetric or chemilumines-
cence detection, respectively. This assay was later adapted
to a high-throughput imaging format with a charge-coupled
device (CCD) camera by coating microtitre plates with im-
Table 5
Examples of enzyme-linked molecularly imprinted sorbent assays
Template Enzyme Affinity, KD (M) Ref.
MIP NIP
2,4-D TOP nd nd [53–55]
Epinephrine HRP 9.2 ± 2 150 ± 15 [56,57]
Atrazine HRP nd nd [56,57]
Phenylephedrine HRP 25 ± 2 100 ± 5 [56]
2,4-D: 2,4-dichlorophenoxyacetic acid; nd: not determined; TOP: tobacco
peroxidase; HRP: horseradish peroxidase.
printed microspheres [54]. The concentration range of the
calibration curve was lowered down to 0.01–100g/ml and
the detection limit to 34 nM. Cross-reactivities were com-
parable with those obtained in a previous radioassay [25]
and when compared to monoclonal antibodies the poly-
mer demonstrated a lower cross-reactivity for methyl ester
2,4-D but higher for 4-chlorophenoxyacetic acid. Adapting
this system to a flow injection ELISA-type chemilumines-
cent MIP assay [55], the same group further improved the
detection limit of 2,4-D allowing the detection of picomole
of analyte with cross-reactivities as previously reported
[53,54]. Piletsky et al. [56,57] developed a technique for
coating microtitre plates with a thin MIP film and per-
formed competitive assays using epinephrine and atrazine
labelled with horseradish peroxidase (HRP). In order to
minimise the non-specific binding of the enzyme conjugate
the assay was performed at pH 6–8. Although, in the case
of atrazine, problems were encountered, related to ionic
repulsion, promising results for the epinephrine assay were
obtained as the polymer was highly specific and the affin-
ity (KD = 9.2 ± 2M) was similar to natural receptors
(KD = 4.6± 0.2M).
5. Conclusion
Although immunoassays are still commonly carried out
using antibodies recent developments have demonstrated
that molecularly imprinted polymers can be viable alterna-
tives.
A number of significant issues and opportunities remain.
In general, binding affinities of MIPs remain lower than
antibodies, although the differential is progressively dimin-
ishing. Implementation of the polymer washing procedures,
though reducing template leaching, should allow the use of
analyte at lower concentration and give access to high affin-
ity binding sites. Recognition by MIPs in aqueous media
needs to be improved, but their excellent ability to perform in
non-aqueous conditions and to recognise non-immunogenic
analytes significantly extends the range of conditions under
which analytes can be determined. Other issue concerns the
use of MIA to analyse real biological samples. Although
few assays analysing samples from serum were reported,
to date only one was performed without prior sample clean
up. This highlight the problems and interferences that can
arise from the component of the biological matrix compare
to the conditions used for fundamental studies.
It is probable that both traditional antibody-based and MIP
sorbent assays will continue to develop in parallel, with each
having superiority in certain areas.
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